Clinical Trial Results: Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of Felzartamab (MOR202), a human anti-CD38 antibody, in IgA nephropathy; study completed with results posted in 2026…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Felzartamab (felzartamab)

Snippet

Sponsor: HI-Bio, A Biogen Company | Conditions: Immunoglobulin A (IgA) Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2026-04-28